Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-03 22:07:24 UTC |
---|
Update Date | 2014-12-24 20:25:35 UTC |
---|
Accession Number | T3D2482 |
---|
Identification |
---|
Common Name | Dapsone |
---|
Class | Small Molecule |
---|
Description | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) |
---|
Compound Type | - Amine
- Anti-Infective Agent
- Anti-Inflammatory Agent
- Antimalarial
- Antimycobacterial
- Drug
- Folic Acid Antagonist
- Leprostatic Agent
- Metabolite
- Organic Compound
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | 1,1'-Sulfonylbis(4-aminobenzene) | 1,1'-Sulfonylbis[4-aminobenzene] | 4,4'-Dapsone | 4,4'-Diaminodiphenyl sulfone | 4,4'-Diaminodiphenyl sulphone | 4,4'-Diaminodiphenylsulfone | 4,4'-Sulfonylbisaniline | 4,4'-Sulfonylbisbenzenamine | 4,4'-Sulfonylbisbenzeneamine | 4,4'-Sulfonyldianilin | 4,4'-sulfonyldianiline | 4-(4-amino-Benzenesulfonyl)-phenylamine | 4-(4-Aminophenylsulfonyl)aniline | 4-(4-Aminophenylsulfonyl)benzenamine | 4-Aminophenyl sulfone | Aczone | Bis(4-aminophenyl)sulfone | Bis(P-aminophenyl) sulfone | DADPS | Dapsona | DAPSONE | Dapsonum | DDS | DDS, pharmaceutical | DIAPHENYLSULFONE | P,P'-diaminodiphenyl sulfone | P,P-Sulphonylbisbenzamine | P,P-Sulphonylbisbenzenamine | P-Aminophenyl sulfone |
|
---|
Chemical Formula | C12H12N2O2S |
---|
Average Molecular Mass | 248.301 g/mol |
---|
Monoisotopic Mass | 248.062 g/mol |
---|
CAS Registry Number | 80-08-0 |
---|
IUPAC Name | 4-(4-aminobenzenesulfonyl)aniline |
---|
Traditional Name | dapsone |
---|
SMILES | NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1 |
---|
InChI Identifier | InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2 |
---|
InChI Key | InChIKey=MQJKPEGWNLWLTK-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Benzenesulfonyl compounds |
---|
Direct Parent | Benzenesulfonyl compounds |
---|
Alternative Parents | |
---|
Substituents | - Benzenesulfonyl group
- Aniline or substituted anilines
- Sulfonyl
- Sulfone
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Primary amine
- Organosulfur compound
- Organonitrogen compound
- Amine
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane
|
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White or creamy white crystalline powder (3) |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 175.5°C | Boiling Point | Not Available | Solubility | 380 mg/L (at 37°C) | LogP | 0.97 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-0564-9770000000-98d678eb70ae9cdbbfaa | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-0a4i-5901100000-901603cf86087b4a4abb | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-0002-0190000000-7de0f1aeb77cf9b122f5 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-0002-0290000000-f1e61c46f1720875a177 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-0a4i-0920000000-ed66532a51b7d047462a | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-0a4l-3900000000-a1f636a2e557bc9b69a5 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-052f-9800000000-3557ad8246dc0a0aa05c | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QTOF , positive | splash10-0a4i-5910000000-0c8eb03605a271970f1d | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QFT , positive | splash10-052b-0590000000-a23b099ad5d2d3cd716d | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QFT , positive | splash10-0a4i-1920000000-0260de715fec538fe8bb | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QFT , positive | splash10-0a4l-5900000000-6ba41fa3598abafdb242 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QFT , positive | splash10-052f-9600000000-d2fe4c5ba425499ba98c | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QFT , positive | splash10-052f-9400000000-e29e2bdac763fc5e250b | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QFT , positive | splash10-066u-9200000000-71494cee2792628e6a0c | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QFT , positive | splash10-014i-9000000000-38433ad894a5e08f6ee0 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QFT , positive | splash10-014i-9000000000-e4782e47ceb05d1ffbda | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QFT , positive | splash10-014i-9000000000-4ab9019e60b1718d1d29 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , positive | splash10-0002-0190000000-d7cf0928be57fafd7ea4 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , positive | splash10-0a4i-1930000000-09cf0e392eeef139f2b1 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , positive | splash10-0a4l-8900000000-5da3a6d058cb14fc8300 | 2017-09-14 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0002-0090000000-77f73a73b1a222285be3 | 2016-06-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0002-0090000000-efb6858364a1d7c22428 | 2016-06-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-004i-9430000000-d9c6fe280d40d0bc8dd6 | 2016-06-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0002-0090000000-f3d8a4bdccbe1170ae6c | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0002-0090000000-ab2b74cff1f89de7c9a9 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0006-9020000000-d4698e6b7c05ce3e71e6 | 2016-08-03 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-052g-8930000000-c51783649020dadfb20f | 2014-09-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, DMSO-d6, experimental) | Not Available | 2014-09-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 22.53 MHz, DMSO-d6, experimental) | Not Available | 2014-09-23 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Ingestion (15, 8); dermal (15, 8) ; eye contact (15, 8); inhalation (15, 8)
Bioavailability is 70 to 80% following oral administration. |
---|
Mechanism of Toxicity | Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood. |
---|
Metabolism | Dapsone is slowly and nearly completely absporbed from GI tract, and distributed throughout the body. It is acetylated in the liver to monoacetyl and diacetyl derivatives. The major metabolite of dapsone is monoacetyldapsone. The rate of acetylation of dapsone is genetically determined and is subject to interindividual variation, although the rate is usually constant for each individual. The drug also is hydroxylated in the liver to hydroxylamine dapsone (NOH-DDS). NOH-DDS appears to be responsible for methemoglobinemia and hemolysis induced by the drug. The metabolites are excreted moslty in the urine. Only minor amounts of dapsone are excreted in feces. (4, 5).
Route of Elimination: Renal
Half Life: 28 hours (range 10-50 hours) |
---|
Toxicity Values | LD50: 496 mg/kg (Oral, Mouse) |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | 3, not classifiable as to its carcinogenicity to humans. (14) |
---|
Uses/Sources | For the treatment and management of leprosy and dermatitis herpetiformis. Dapsone is mainly employed for its actions against mycobacterium leprae. It is also used with pyrimethamine in the treatment of malaria, and of Pneumocystis carinii pneumonia (PCP) (1, 15). |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Methemoglobinemia and hemolysis are the main risks of acute intoxication. Hemolytic anemia, agranulocytosis, aplastic anemia and other blood dyscrasias may occur in chronic poisoning. Target organs are central and peripheral nervous systems, blood, liver and skin. Methemoglobinemia is the principal and constant feature of dapsone poisoning. Hemolytic anaemia and agranulocytosis may occur with the relatively low doses used for leprosy and malaria, whereas peripheral neuropathy and hepatitis are only observed with the higher doses used in the treatment of dermatitis herpetiformis. (16). |
---|
Symptoms | Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary. |
---|
Treatment | Administer charcoal as a slurry following oral or parenteral exposure. (9) |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00250 |
---|
HMDB ID | HMDB14395 |
---|
PubChem Compound ID | 2955 |
---|
ChEMBL ID | CHEMBL1043 |
---|
ChemSpider ID | 2849 |
---|
KEGG ID | C07666 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 4325 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Dapsone |
---|
PDB ID | Not Available |
---|
ACToR ID | 377 |
---|
Wikipedia Link | Dapsone |
---|
References |
---|
Synthesis Reference | Weijiard, J.and Messerly, J.P.; U.S. Patent 2,385,899; October 2,1945; assigned to Merck
& Co., Inc. |
---|
MSDS | Link |
---|
General References | - Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. [18048412 ]
- Chu RC, Begley JA, Colligan PD, Hall CA: The methylcobalamin metabolism of cultured human fibroblasts. Metabolism. 1993 Mar;42(3):315-9. [8487649 ]
- Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF, Chen TC: Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 2006 Jul-Aug;26(4A):2567-72. [16886665 ]
- Sakaki T, Kagawa N, Yamamoto K, Inouye K: Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119-34. Print 2005 Jan 1. [15574355 ]
- Tokar EJ, Webber MM: Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis. 2005;22(3):275-84. [16158255 ]
- Malfara WR, Pereira CP, Santos AC, Queiroz RH: Effects of H(2)-receptor antagonists on dapsone-induced methaemoglobinaemia in rats. Pharmacol Res. 2002 Apr;45(4):269-73. [12030789 ]
- FLOCH H, GELARD AM: [Study of 4,4'-bis(ethylamino)-diphenylsulfone and of N-succinyl-4,4'diaminodiphenylsulfone administered intramuscularly in depot form]. Publ Inst Pasteur Guyane Fr Inini. 1954 Oct;15(343):1-7. [14377653 ]
- Lewis RJ (1996). Sax's Dangerous Properties of Industrial Materials. 9th ed. Volumes 1-3. New York, NY: Van Nostrand Reinhold.
- Rumack BH (2009). POISINDEX(R) Information System. Englewood, CO: Micromedex, Inc. CCIS Volume 141, edition expires Aug, 2009.
- McEvoy GK (ed) (1998). American Hospital Formulary Service-Drug Information 19 98. Bethesda, MD: American Society of Health-System Pharmacists, Inc. (Plus Supplements).
- Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman AG (eds) (1996). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill.
- Osol A, Hoover JE, et al. (eds) (1975). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co.
- Martindale, The Extra Pharmacopoeia, 30th ed, p157-8
- International Agency for Research on Cancer (2014). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. [Link]
- Wikipedia. Dapsone. Last Updated 2 August 2009. [Link]
- International Programme on Chemical Safety (IPCS) INCHEM (1993). Poison Information Monograph for Dapsone. [Link]
- Drugs.com [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|